Drugs / BK-specific T cells from Donor Lymphocytes
BK-specific T cells from Donor Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05042076 | Dec 2021 → May 2024 | BK-virus nephropathy, disease related to solid organ transplantation | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BK-specific T cells from Donor Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042076 ↗ |
| Modality | Cell therapy | “Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells” NCT05042076 ↗ |
| Route | Intravenous | “IV bolus injection; IV push of IMP over approximately 2-4 minutes” NCT05042076 ↗ |